Studies in the Human Frontal Cortex: Evidence for Changes in Neurochemical Markers in Schizophrenia and Bipolar Disorder
Commonality of treatments in schizophrenia and bipolar disorder suggest that there may be a single pathology driving some of the symptoms of these illnesses. To test this hypothesis, the literature on the changes in the molecular neuroanatomy of postmortem brain tissue from subjects with schizophrenia and bipolar disorder has been reviewed to attempt to identify a common neurobiology. Such studies provide evidence to suggest that changes in the serotonergic system of the frontal cortex may be such a common factor. However, currently available data does not support the argument that the same changes in the serotonergic systems of the frontal cortex are present in schizophrenia and bipolar disorder. By contrast, such data would suggest that targeting receptor-G-protein interactions might be therapeutically beneficial in both illnesses.
KeywordsBipolar Disorder Frontal Cortex Serotonin Receptor Serotonin Transporter Serotonergic System
Unable to display preview. Download preview PDF.
- Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, and Lewis DA. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. A J Psychiatry 1999; 156: 1580–1589.Google Scholar
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders (Forth edition). American Psychiatric Association, Washington, D.C., 1994.Google Scholar
- Calabrese JR, Bowden V, and Woyshville MJ. Lithium and the anticonvilsants in bipolar disorder. In: Bloom FE and Kupfer DJ, (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press,New York, 1995; pp 1099–1111.Google Scholar
- Dean B, Pavey G, McLeod M, Opeskin K, Keks N, and Copolov D. Evidence for an abnormality in the assembly of the GABAA receptor in the prefrontal cortex of subjects with bipolar disorder. J Affect Dis 2000; (In press).Google Scholar
- Dean B, Tomaskovic-Crook E, Opeskin K, Keks N, and Copolov D. No change in the density of the serotoninlA receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem Int 1999b; 34: 109–115.PubMedCrossRefGoogle Scholar
- Friedman E and Wang HY. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. J Neurochem 1996; 67: 1145 1152.Google Scholar
- Fuster JM. The Prefrontal Cortex: Anatomy, Physiology and Neuropsychology of the Frontal Lobe. Raven Press, New York, 1989.Google Scholar
- Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 1995;1, Suppl 15: 4S - 10S.Google Scholar
- Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, and Watson SJ. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry 1997; 54: 1089–1095.PubMedCrossRefGoogle Scholar
- Wirshing WC, Marder SR, Van Putten T, and Ames D. Acute treatment of schizophrenia. In: Bloom FE and Kupfer DJ, (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, 1995; pp 1259–1275.Google Scholar